Expanded approvals in 2016 increase options.
By Jennifer L.W. Fink
The treatment of non–small cell lung cancer (NSCLC) took another leap forward in 2016 with approvals from the U.S. Food and Drug Administration (FDA) for expanded and refined uses of four cancer drugs, including the first-ever approval of an immunotherapy as a first-line treatment for lung cancer.
Learn More- Cancer Today
